Cargando…

Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells

Advanced colon cancer is a malignancy with poor response to various treatment modalities including ionising radiation (IR) and chemotherapy. Both IR and chemotherapeutic agents have been shown to act by inducing apoptosis, a type of cell death antagonised by the Bcl-x(L) gene product. Since approxim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wacheck, V, Selzer, E, Günsberg, P, Lucas, T, Meyer, H, Thallinger, C, Monia, B P, Jansen, B
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394316/ https://www.ncbi.nlm.nih.gov/pubmed/14520471 http://dx.doi.org/10.1038/sj.bjc.6601254

Ejemplares similares

The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
por: Sangar, V K, et al.
Publicado: (2004)

Inhibition of ICAM2 induces radiosensitisation in oral squamous cell carcinoma cells
por: Ishigami, T, et al.
Publicado: (2008)

Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides
por: Lau, J P, et al.
Publicado: (2004)

Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor
por: Shi, W, et al.
Publicado: (2002)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation
por: Souchek, J J, et al.
Publicado: (2014)

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
por: Gagliardi, Maria, et al.
Publicado: (2022)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
por: Nielsen, T O, et al.
Publicado: (2013)

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
por: Jonsson, Marte, et al.
Publicado: (2016)

H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma
por: Zhang, Wenyan, et al.
Publicado: (2018)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model
por: Harrington, K J, et al.
Publicado: (2004)

Bcl‐X(L) Antisense Sensitizes Human Colon Cancer Cell Line to 5‐Fluorouracil
por: Nita, Marcelo Eidi, et al.
Publicado: (2000)

Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines
por: Playle, L C, et al.
Publicado: (2002)

Targeted delivery of antisense oligonucleotides to pancreatic β-cells
por: Ämmälä, C., et al.
Publicado: (2018)

Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides
por: Lo, Yu-Li, et al.
Publicado: (2014)

Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015)

Correction: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides
Publicado: (2014)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
por: McPhillips, F, et al.
Publicado: (2001)

Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
por: Setoguchi, Kiyoko, et al.
Publicado: (2017)

Antisense Morpholino Oligonucleotides Reduce Neurofilament Synthesis and Inhibit Axon Regeneration in Lamprey Reticulospinal Neurons
por: Zhang, Guixin, et al.
Publicado: (2015)

Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations
por: Huang, Lulu, et al.
Publicado: (2019)

Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
por: Cummings, J, et al.
Publicado: (2005)

Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines
por: Sekhon, J, et al.
Publicado: (2002)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas
por: Kelly, J D, et al.
Publicado: (2004)

Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
por: Tasfaout, Hichem, et al.
Publicado: (2017)

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016)

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
por: Cummings, J, et al.
Publicado: (2006)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n7pn9oda86u8269udb5ecatfqa